A New Preventative Strategy Targeting a Specific Novel Protein against Human Bone Metastases

自1981年以来，我国的主要死亡原因一直是癌症。2002年死于癌症的总人数达到304 286人，死亡率为每10万人241.5人，占2002年所有死亡人数的31.0%。在25-50%的晚期癌症患者中发现骨转移，并且据认为目前有70，000 - 150，000名晚期癌症患者患有骨转移。骨骼是癌症转移的常见部位。维持这些患者的生活质量是一个紧迫的问题，以帮助这些患者生活在充分的尊严。因此，我们正在利用医学技术，通过蛋白质组学来鉴定骨转移的分子靶蛋白，以便以低成本进行早期诊断。根据厚生劳动省、文部科学省和经济省的“人类基因组/遗传学研究伦理指南”，对患者样本供体的姓名进行盲法。 ...更多信息 de和Industry，以及FDA 21 CFR第11部分。使用血清中的蛋白质组学模式通过SELDI-TOF（BioRad）鉴定骨转移肿瘤。在47例肝癌患者中进行了一项前瞻性研究，以确定哪些蛋白质是骨转移的特征和预测。在这些患者中，11例发生骨转移，并且在所有患者的骨造影中证实骨转移之前鉴定出该蛋白。该结果产生了100%的灵敏度。此外，在这些患者中，10例患者的蛋白质出现峰值。目前，由于骨造影结果未显示骨转移，因此正在进行随访调查。我们鉴定的蛋白质的一个重要特征是，在这些患者中，在诊断前的大约平均6-11个月，它是可检测的，比骨转移可以通过骨显像成像要早得多。此外，我们通过质谱法从曲线下面积定量该蛋白，发现该蛋白在血清中持续增加，直到通过骨密度图确认骨转移时，然后在放射治疗开始后下降。[This蛋白质显示以下重要意义成为骨转移的生物标志物]1。准备的病人来衡量是血清。2.测量时间短。3.这种蛋白比骨密度成像更早识别。[This蛋白对骨转移显示以下重要的临床意义]1。能够预防骨转移。我们可以制造这种蛋白质的抑制剂。对预防骨转移药物的展望.骨转移的疼痛将永远消失。癌症患者的长寿期望：我们已经使用蛋白质组学技术鉴定了一种新的蛋白质作为骨转移的分子靶点，并证明了其在低成本的早期诊断中的潜在用途。现在需要大规模的临床试验来证明这种方法的有效性，但是使用这种蛋白质进行早期诊断的潜力也可以在未来实现更有效的骨转移治疗。少

The leading cause of death in our country has been cancer since 1981. The total number of deaths from cancer reached 304,286 in 2002, with a mortality rate of 241.5 per 100,000, accounting for 31.0% of all deaths in 2002. Bone metastasis is found in 25-50% of terminal cancer patients, and it is thought that 70,000-150,000 terminal-stage cancer patients are presently suffering from bone metastasis. Bones are common sites for cancer metastases. Maintaining the QOL of these patients is an urgent concern in order to help these patients live with full dignity. Therefore we are using medical technology to identify molecular target proteins of bone metastasis using proteomics in order to facilitate early diagnosis at low cost. Names of the donors of patient samples were blinded in accordance with the 'Ethical Guidelines for Human Genomic/Genetic Studies' of the Ministry of Health, Labor, and Welfare, Ministry of Education, Culture, Sports, Science, and Technology, and Ministry of Economy, Tra … More de, and Industry, and the FDA 21 CFR part 11. Use of proteomics patterns in serum to identify bone metastasis tumor by SELDI-TOF (BioRad). A prospective study was undertaken in 47 patients with liver cancer, to identify which proteins were characteristic and predictive of bone metastasis. Of these patients, bone metastasis developed in 11 cases, and this protein was identified before bone metastasis was confirmed in bone scintigraphy of all patients. This result yielded a sensitivity of 100%. Also, among these patients, peak values of the protein were found in 10 cases. At present, the follow-up investigation is under way because the results of bone scintigraphy did not reveal bone metastasis. An important characteristic of the protein we identified was that it was detectable at about average at 6-11 months before diagnosis in these patients, much earlier than bone metastases can be imaged by bone scintigraphy. In addition, we quantified this protein from the areas under the curves by mass spectrometry, and found that the protein continued to increase in serum up to the time when bone metastasis was confirmed by bone scintigraphy and then decreased after the start of radiotherapy treatment.[This protein shows below important significance to become biomarker of bone metastasis]1. Preparation of the patient to measure is serum.2. Measurement time is short.3. This protein recognized earlier than bone scintigraphy.[This protein shows below important clinical significance to bone metastasis]1. Prevention of bone metastasis is enabled.2. We can make inhibitor of this protein. Expectation to pharmaceuticals for prevention of bone metastasis.3. The pain of bone metastasis will be gone eternally.4. Macrobiotic expectation of the cancer patients.We have used proteomics technology to identify a novel protein as a molecular target for bone metastasis and demonstrated its potential use for early diagnosis at low cost. Large-scale clinical trials will now be needed, to prove the usefulness of this approach, but the potential offered for early diagnosis using this protein could also enable far more effective treatment for bone metastasis in the future. Less